

**Emerging Science Reviews** are published on an occasional basis to highlight areas of research that are very recent and at the cutting edge of cardiovascular biology. The goal of these articles is to bring attention to promising new topics that are not yet well developed.

## MicroRNA in Cardiovascular Calcification

### Focus on Targets and Extracellular Vesicle Delivery Mechanisms

Claudia Goetsch, Joshua D. Hutcheson, Elena Aikawa

**Abstract:** Cardiovascular calcification is a prominent feature of chronic inflammatory disorders—such as chronic kidney disease, type 2 diabetes mellitus, and atherosclerosis—that associate with significant morbidity and mortality. The concept that similar pathways control both bone remodeling and vascular calcification is widely accepted, but the precise mechanisms of calcification remain largely unknown. The central role of microRNAs (miRNA) as fine-tune regulators in the cardiovascular system and bone biology has gained acceptance and has raised the possibility for novel therapeutic targets. Additionally, circulating miRNAs have been proposed as biomarkers for a wide range of cardiovascular diseases, but knowledge of miRNA biology in cardiovascular calcification is very limited. This review focuses on the role of miRNAs in cardiovascular disease, with emphasis on osteogenic processes. Herein, we discuss the current understanding of miRNAs in cardiovascular calcification. Furthermore, we identify a set of miRNAs common to diseases associated with cardiovascular calcification (chronic kidney disease, type 2 diabetes mellitus, and atherosclerosis), and we hypothesize that these miRNAs may provide a molecular signature for calcification. Finally, we discuss this novel hypothesis with emphasis on known biological and pathological osteogenic processes (eg, osteogenic differentiation, release of calcifying matrix vesicles). The aim of this review is to provide an organized discussion of the known links between miRNA and calcification that provide emerging concepts for future studies on miRNA biology in cardiovascular calcification, which will be critical for developing new therapeutic strategies. (*Circ Res.* 2013;112:1073-1084.)

**Key Words:** aortic valve stenosis ■ cardiovascular diseases ■ circulating miRNA ■ diabetes mellitus, type 2 ■ extracellular vesicles ■ microRNAs ■ renal insufficiency, chronic ■ vascular calcification

MicroRNAs (miRNAs) are a large class of evolutionarily conserved, small, endogenous, noncoding RNAs serving as essential post-transcriptional modulators of gene expression that play a crucial role in normal physiology.<sup>1</sup> miRNAs can be transcribed in parallel with host transcripts through 2 different transcription classes, exonic and intronic.<sup>2</sup> Independent expression from intronic promoters could explain why host gene and miRNA expression do not always directly correlate.<sup>3</sup> Another level of regulatory biological control of miRNAs are sponge RNAs, which act as a decoy for miRNAs.<sup>4</sup> miRNAs regulate biological processes by binding to mRNA 3'-untranslated region sequences to attenuate protein synthesis or mRNA

stability.<sup>5</sup> Acting as genetic switches or fine-tuners, miRNAs are key regulators of diverse biological and pathological processes, including development, organogenesis, apoptosis, and cell proliferation and differentiation. In addition to these known physiological roles, miRNA dysregulation often results in impaired cellular function and disease progression.<sup>5</sup> The detailed regulation of miRNA biogenesis in cardiovascular disease is reviewed elsewhere.<sup>6</sup> The central role of miRNAs as fine-tune regulators in the cardiovascular system is still under investigation; however, miRNAs have received little attention in cardiovascular calcification—one of the most severe pathological outcomes associated with cardiovascular disease.

Received August 31, 2012; revision received February 4, 2013; accepted February 6, 2013. In January 2013, the average time from submission to first decision for all original research papers submitted to *Circulation Research* was 12.2 days.

From the Center for Interdisciplinary Cardiovascular Sciences, and Center for Excellence in Vascular Biology, Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115

Correspondence to Elena Aikawa, MD, PhD, Harvard Medical School, Cardiovascular Medicine, Brigham and Women's Hospital, 77 Avenue Louis Pasteur, NRB-741, Boston, MA 02115, Phone: 617-730-7755, Fax: 617-730-7791, Email: eaikawa@partners.org

© 2013 American Heart Association, Inc.


*Circulation Research* is available at <http://circres.ahajournals.org>

DOI: 10.1161/CIRCRESAHA.113.300937

Nonstandard Abbreviations and Acronyms	
<b>Ago</b>	argonaute
<b>ALP</b>	tissue nonspecific alkaline phosphatase
<b>BMP</b>	bone morphogenetic protein
<b>CAD</b>	coronary artery disease
<b>CKD</b>	chronic kidney disease
<b>Dkk-1</b>	dickkopf 1
<b>KLF</b>	krüppel-like factor
<b>miRNA</b>	microRNA
<b>Pi</b>	inorganic phosphate
<b>SMC</b>	smooth muscle cells
<b>T2D</b>	type 2 diabetes mellitus
<b>Wnt</b>	wingless-type MMTV integration site family member

Cardiovascular calcification is a major characteristic of chronic inflammatory disorders—such as chronic kidney disease (CKD), type 2 diabetes mellitus (T2D), and atherosclerosis—that are associated with significant morbidity and mortality. The precise mechanisms of calcification within the vessel wall or heart valve leaflets remain largely unknown, but the concept that pathways controlling bone remodeling also occur in the cardiovascular system is well accepted. Indeed, vascular calcification is correlated with osteoporosis in humans and animal models<sup>7</sup>—the so-called calcification paradox.<sup>8</sup> The physiological balance between induction and inhibition of calcification becomes dysregulated in CKD, T2D, and atherosclerosis, leading to calcification at several sites in the cardiovascular system, including the intima and media of vessels and the cardiac valves.<sup>8</sup> Atherosclerotic calcification occurs as a part of the atherogenic progress in the vessel intima with small hydroxyapatite mineral crystals (microcalcifications) that seem to associate with cholesterol crystals observed in early lesions.<sup>9</sup> Medial calcification occurs primarily in association with CKD and T2D, independently of hypercholesterolemia. Calcification of the aortic valve is associated with many of the same risk factors as intimal and medial calcification and leads to impaired movement of aortic valve leaflets, resulting in valve dysfunction. All three of these processes share risk factors and etiologic factors, including inflammation and oxidative stress, that appear to lead to changes in phenotype of resident or circulating progenitor cells.

Vascular calcification is an active, cell-regulated process (Figure 1). Various studies provide evidence of phenotypic transition/dedifferentiation of mature smooth muscle cells (SMCs) into an osteogenic phenotype—a key feature in vascular calcification. Osteogenic transition of vascular SMCs or stem cells is induced by bone morphogenetic proteins, inflammation, oxidative stress, or high phosphate levels, and leads to a unique molecular pattern marked by osteogenic transcription factors.<sup>10</sup> In medial calcification, SMCs undergo dedifferentiation from a contractile to a proatherogenic synthetic phenotype, lose the expression of their marker genes, acquire osteogenic markers, and deposit a mineralized bone-like matrix. The major lineage source of osteogenic cells within the calcified atherosclerotic intimal lesion are SMCs; however, circulating bone marrow-derived cells also contribute to early



**Figure 1. Major pathways/molecules involved in cardiovascular calcification.**

osteochondrogenic differentiation in atherosclerotic vessels.<sup>11</sup> Recently, a novel concept emerged that circulating cells harboring osteogenic potential can home to atherosclerotic lesions and contribute to intimal calcification.<sup>12,13</sup> Independent of the cell type, it seems that master transcription factors, including Runx2/Cbfa1, Msx2, and osterix (SP7), designate cells for osteoblast lineages through the induction of downstream genes such as alkaline phosphatase (ALP), and osteocalcin. Runx2 acts as a critical regulator of osteogenic lineage and a modulator of bone-related genes<sup>14</sup> and is essential and sufficient for driving SMC calcification.<sup>15–17</sup>

Discovered in the bone biology field, a program of miRNAs controls Runx2 expression to prevent skeletal disorders.<sup>18</sup> Three of these miRNAs (miR-133a, miR-135a, and miR-218) are altered in the circulation of patients with cardiovascular diseases.<sup>19–22</sup> Additionally, circulating miRNAs have been proposed as biomarkers for a wide range of cardiovascular diseases, but knowledge of circulating miRNA in cardiovascular calcification is scant. No pattern of miRNA has been reported for vascular calcification; however, as new studies emerge, it may be helpful to understand the role of miRNAs in diseases and cellular signaling processes known to be associated with calcification. Therefore, in this review we begin by discussing the current, limited understanding of miRNA in cardiovascular calcification. We then document a set of circulating miRNAs, which is dysregulated in certain cardiovascular diseases (eg, CKD, T2D, atherosclerosis), and we propose a potential circulating miRNA signature for vascular calcification. We discuss this novel hypothesis with emphasis on known biological and pathological osteogenic processes (eg, osteogenic differentiation, release of calcifying matrix vesicles). Furthermore, we summarize and discuss miRNAs that control bone osteogenesis and link them to potential regulation of cardiovascular calcification.

### miRNA in Cardiovascular Calcification and Osteogenesis

Evidence for the role of miRNAs in cardiovascular calcification is very limited (Table 1). However, we recently provided

**Table 1. Specific miRNAs, Their Targets, and Effects in Cardiovascular Calcification**

miRNA/Regulation	Target	Cell Source	Observation by Using Inhibitor/Mimic	Reference number
miR-125b ↓	<b>SP7</b>	Human CASMC	Inhibit ALP activity and matrix mineralization	23
	—	Porcine VIC	Blocks TGF- $\beta$ -mediated ALP activity	44
miR-223 ↑	<b>Mef2c</b> <b>RhoB</b> <b>SM<math>\alpha</math> actin</b>	Human SMC	Enhance VSMC migration	32
miR-143 miR-145 ↓	<b>KLF4</b>	Human SMC	—	32
miR-30d/e ↓	Runx2	Human SMC	Inhibit ALP activity and matrix mineralization	42
miR-204 ↓	Runx2	Mouse SMC	Inhibit ALP activity and osteocalcin secretion	28
miR-29a/b ↓	ADAMTS-7	Rat SMC	Inhibit matrix mineralization	52
miR-135a*, miR-762, miR-714, or miR-712*↑	<b>NCX1</b> <b>PMCA1</b> <b>NCKX4</b>	Mouse SMC	Promote matrix mineralization	25

Bold indicates direct binding to 3' untranslated region not shown in this study; and arrow indicates regulation of miRNA.

ALP indicates alkaline phosphatase; CASMC, coronary artery smooth muscle cell; miRNA, microRNA; SMC, smooth muscle cell; TGF, transforming growth factor; and VSMC, vascular smooth muscle cell.

the first miRNA-dependent mechanism in the progression of vascular calcification by demonstrating that miR-125b dysregulation leads to the transition of human coronary arterial SMCs into osteoblast-like cells partially by targeting the transcription factor osterix.<sup>23</sup> Inhibition of miR-125b promoted ALP activity and matrix mineralization in vitro. Correspondingly, in vivo observations indicate that miR-125b decreased in calcified aortas of apolipoprotein-deficient (*ApoE*) mice fed a high-fat diet for 26 weeks compared with those euthanized after 10 weeks.<sup>23</sup> Additionally, miRNA-processing enzymes DROSHA and DICER—essential for SMC function<sup>24</sup>—were reduced in calcified SMCs.<sup>23</sup>

Using the Exiqon mercury Locked Nucleic Acids microRNA array, Gui et al found 20 altered miRNAs in the aortic media of *klotho* mutant (*kl/kl*) mice.<sup>25</sup> *Kl/kl* mice display vascular calcification attributable to hyperphosphatemia and through a Runx2-dependent mechanism, presenting the symptoms of CKD-associated bone and mineral disorders.<sup>26</sup> Seventeen miRNAs were increased and 3 decreased (miR-1, miR-93, miR-302b) in *kl/kl* mice compared with wild-type mice. An increased expression of miR-135a\*, miR-762, miR-714, and miR-712\* was detected in Ca/inorganic phosphate (Pi)-stimulated vascular SMC isolated from WT mice and within the aortic media of *kl/kl* mice and is correlated with decreased expression of their potential target genes NCX1, PMCA1, and NCKX4—all Ca<sup>2+</sup> efflux proteins. This disruption of Ca<sup>2+</sup> transporters and the resultant increase in intracellular Ca<sup>2+</sup> concentrations could be involved in medial SMC calcification.<sup>25</sup> It is important, however, to mention that functional studies altering 1 single miRNA (miR-135a\*, miR-762, miR-714, or miR-712\*) by mimics or inhibitors failed to show an effect on SMC calcification, whereas inhibition of all 4 miRNAs together significantly reduce calcium content

of SMC by 30%. miR-680 served as control, because it was the most highly upregulated miRNA in the aortic media of *kl/kl* mice. The failure of miR-680 specific inhibitor to reduce SMC calcification resulted in the conclusion that miR-135a\*, miR-762, miR-714, and miR-712\* are specifically involved in calcification. Indeed it has been shown that miRNAs often function in clusters; however, it is still unknown whether the cluster is limited to these 4 miRNAs. Additionally, the role of the other 15 highly regulated miRNAs in *kl/kl* mice needs to be determined.

miR-204, a known inhibitor of osteoblastogenesis,<sup>27</sup> and one candidate of the Runx2-miRNA-cluster in osteoblasts,<sup>18</sup> was also recently found to contribute to SMC calcification in vitro and in vivo.<sup>28</sup> In vitro, miR-204 was identified to be a negative regulator of SMC calcification through direct targeting the 3' untranslated region of the Runx2 gene in mouse SMCs cultured in calcifying media consisting of 10 mmol/L  $\beta$ -glycerolphosphate.<sup>28</sup> Similarly, in a mouse model of vitamin D3-induced vascular calcification, overexpression of miR-204 by agomiRs decreased medial calcification and Runx2 expression mostly to control level within 3 days of treatment.<sup>28</sup>

As mentioned above, osteogenic differentiation of SMCs is also characterized by a loss of traditional SMC markers. Changes in the expression levels of the miR-143/145 cluster promotes differentiation and represses proliferation of SMCs thereby maintaining the SMC phenotype;<sup>29–31</sup> and have also been linked to vascular calcification. Exposure of human primary SMC to pathophysiological levels of Pi decreased miR-143 and miR-145 expression. Similarly, these miRNAs are downregulated in the aorta of 20-week-old *ApoE*-deficient mice.<sup>32</sup> Even though studies have yet to establish a direct functional role of miR-143 and miR-145 in vascular calcification, this hypothesis is supported by findings noted in literature of

diseases associated with calcification. miR-145 promotes SMC differentiation by targeting Krüppel-like factor (KLF) 4,<sup>30</sup> and KLF4 mediates high phosphate-induced transition of SMCs into osteogenic cells.<sup>33</sup> Inhibition of miR-143/145 promotes a phenotypic switch to the synthetic, proatherogenic SMC state,<sup>29</sup> including the inhibition of SMC marker (eg,  $\alpha$ -smooth muscle actin and smooth muscle myosin heavy chain<sup>34</sup>)—both diminished in osteogenic SMCs.<sup>35</sup> Additionally, circulating miR-145 levels are reduced in patients with coronary artery disease (CAD).<sup>19</sup> Moreover, miR-145 was identified as part of the specific miRNA profile of destabilized human plaques,<sup>36</sup> a biomechanical failure of the plaque that may involve microcalcification.<sup>37,38</sup>

In mediating these cellular changes, the paracrine osteogenic signals facilitated by morphogens of the bone morphogenetic protein (BMP) and wingless-type MMTV integration site family member (Wnt) superfamilies, are effective regulators of vascular and valvular calcification, but also necessary in controlling skeletal osteogenesis.<sup>39</sup> Two members of the BMP signaling pathway (reviewed in detail elsewhere),<sup>39</sup> BMP-2 and BMP-4 are potent osteogenic differentiation factors detected in calcified areas of atherosclerotic lesions.<sup>40,41</sup> BMPs elicit their effects through activation of a receptor complex composed of type I and type II receptors and activate receptor type-dependent and ligand-dependent Smad transcription factors, which modulate the expression of Runx2.<sup>39</sup>

A recent study indicated that BMP-2 promotes SMC calcification by decreasing the expression of miR-30b by 6.2-fold and miR-30e by 5.5-fold though an Smad-independent pathway that leads to a direct increase in Runx2.<sup>42</sup> Using antagomirs to block these miRNAs it was found that downregulation of miR-30b and miR-30e in vitro is sufficient to increase Runx2 expression, even in the absence of BMP-2. Accordingly, calcified human coronary arteries demonstrate higher BMP-2 levels and lower levels of miR-30b than noncalcified coronary arteries. Similar miRNA modulations of BMP-2 signaling have been observed in studies of heart valve calcification. Nigam et al recently identified a miRNA pattern specific to aortic stenosis, which is typically caused by calcific aortic valve disease, using whole bicuspid valves.<sup>43</sup> miR-30b was decreased in the aortic valves of patients requiring replacement as a result of aortic stenosis, compared with those requiring replacement as a result of aortic insufficiency.<sup>43</sup> Another group compared bicuspid and tricuspid aortic valve leaflets by miRNA microarray and found a number of modulated miRNAs.<sup>44</sup> Particularly, miR-141 had the most dramatic change, showing a 14.5-fold decrease in the bicuspid versus tricuspid valves; however, the levels of calcification were comparable between the two groups. In vitro, miR-141 represses the valvular interstitial cell, the resident cell within cardiac valve leaflets, response to osteogenic stimuli, in part through blocking BMP2-dependent calcification.<sup>44</sup> Likewise, Itoh et al identified miR-141 as a preosteoblast differentiation-related miRNA, which modulated the BMP2-induced preosteoblast differentiation by direct translational repression of Dlx5, a transcription factor for osterix.<sup>45</sup> miR-26a is another miRNA, which is repressed in aortic valve leaflets of patients with aortic stenosis.<sup>43</sup> miR-26a was previously identified as a Smad-regulating miRNA related to osteoblastogenesis; it

functionally represses osteoblast differentiation by targeting Smad1 and Smad5 expression.<sup>46</sup> Human aortic valvular interstitial cells showed decreased mRNA levels of both BMP-2 and Smad1 when treated with a miR-26a mimic.

Although BMP-2 is a known inducer of osteogenic differentiation, activation of Wnt signaling is crucial for controlling osteoblast function<sup>47</sup> and for the programming of vascular cells during cardiovascular calcification.<sup>39</sup> Activation of the Wnt/ $\beta$ -catenin signaling pathway occurs in human calcified aortic valve stenosis,<sup>48</sup> in low-density lipoprotein-deficient mice<sup>49,50</sup> and in osteogenic SMCs in vitro.<sup>51</sup> miR-29a potentiates osteoblastogenesis by modulating Wnt signaling. Interestingly, miR-29a/b was repressed in high-phosphate-induced calcifying rat SMC, calcified abdominal aortas from rats with CKD induced by 5/6 nephrectomy, and human radial arteries with chronic kidney failure.<sup>52</sup> miR-29a/b directly targeted a disintegrin and metalloproteinase with thrombospondin motifs-7 (ADAMTS-7) as shown by luciferase assay. A miR-29a/b mimic inhibited, and a miR-29a/b inhibitor enhanced, high-phosphate-induced SMC calcification though alteration of ADAMTS-7, BMP-2, p-Smad 1/5/8, and Runx2 protein expression. Because miR-29 also associated with reduced extracellular matrix components, such as collagen and elastin,<sup>53</sup> low cellular miR-29a/b levels may also cause vascular thickening, fibrosis, and elastolysis, which accelerate arterial and aortic valve calcification.<sup>54</sup>

Likewise, the canonical Wnt signaling induces miR-29a expression, which negatively targets regulators of Wnt signaling, including Dickkopf (Dkk) 1, sFRP2, Kremen, and osteonectin.<sup>55,56</sup> Dkk1 is an extracellular antagonist of the canonical Wnt signaling that plays a crucial role in bone remodeling.<sup>57,58</sup> Dkk1 was also shown to prevent vascular calcification by preventing warfarin-induced activation of  $\beta$ -catenin, and osteogenic transdifferentiation of SMCs<sup>59</sup> and tumor necrosis factor  $\alpha$ -induced induction of ALP activity.<sup>49</sup> Dkk1 serum levels in CKD patients correlate negatively with arterial stiffness,<sup>60</sup> and matrix metalloproteinase-2, another target of miR-29,<sup>61</sup> promotes arterial calcification in CKD.<sup>62</sup>

Studies about miRNA expression in human calcified tissue are rare (Table 2). Li et al analyzed the expression of miRNAs in patients with peripheral artery disease (arteriosclerosis obliterans), characterized by fibrosis of the tunica intima and calcification of the tunica media.<sup>63</sup> miR-21, miR-130a, miR-27b, let-7f, and miR-210 were significantly increased, whereas miR-221 and miR-222 were decreased in the sclerotic intima samples, compared with normal vessels.<sup>63</sup> Higher levels of miR-21 and miR-210 were confirmed in a study that compared atherosclerotic lesions with nonatherosclerotic left internal thoracic arteries.<sup>64</sup> miR-210 is known to promote osteoblast differentiation though the inhibition of the BMP co-receptor activin type IB receptor (ALK4).<sup>65</sup> In line with this evidence, activin—a ligand for ALK4<sup>66</sup>—inhibits SMC mineralization.<sup>67</sup> Another study found a different miRNA pattern using atherosclerotic plaque material from the carotid artery, compared with a specimen from the arteria mammaria interna as control tissue.<sup>20</sup> The healthy vessel expressed higher levels of miR-520b and miR-105, whereas miR-10b, miR-218, miR-30e, miR-26b, and miR-125a were predominantly expressed in atherosclerotic plaque.<sup>20</sup> The investigators in these studies,



**Table 2. miRNAs Expressed in Human Atherosclerotic/Calcified Tissue**

miRNA	Disease	Tissue Type	Finding	Control Tissue	Reference Number
miR-21, -34a, -146a,-146b-5p, -210	CAD	Atherosclerotic arteries	Increased	Non-atherosclerotic left internal thoracic arteries	64
miR-105, -520b	CAD	Atherosclerotic carotid artery	Decreased	Arteria mammaria interna	20
miR-10b, -26b, -30e, -125a, -218, miR-30b	CAD	Calcified carotid artery	Increased		
	CAD	Calcified carotid artery	Decreased	Noncalcified carotid artery from non CAD patients	42
miR-100, -127, -133a,b-145	CAD	Destabilized plaque	Increased	Stabilized plaque	21
miR-221, -222	AO	Sclerotic intima from lower extremities vessels	Decreased	Nonsclerotic intima from lower extremities vessels	63
miR-21, -27b, -210, -130a, let-7f			Increased		
miR-22, -27a, -141, -124,-125b, -185, -187, -194, -211, -330, -370, -449,-486, -551, -564, -575, -585, -622, -637, -648, -1202,-1282, -1469, -1908, -1972	AS	Bicuspid aortic valve	Decreased	Tricuspid aortic valve	44
miR-30e, -32, -145, -151, -152, -190, -373, -768			Increased		
miR-26a, -30b, -195	AS	Whole bicuspid valves	Decreased	Replacement due to aortic insufficiency	43

Bold indicates found in >1 study; and italic, found also in circulation (Table 3).

AO indicates arteriosclerosis obliterans; AS, aortic stenosis; and CAD, coronary artery disease.


however, did not examine calcification levels to determine a potential correlation with the observed changes in miRNA.

In addition to the osteoblastogenesis of SMCs, the contribution of osteoclasts, bone resorbing cells that play an active role in normal bone physiology, to vascular calcification is controversial and poorly understood.<sup>12</sup> The observation of osteoclast-like cells in calcified atherosclerotic lesions suggested this bone-related cell is active in the vessel wall. The evidence was strengthened recently by Sun et al, who demonstrated the functional role of SMC-derived Runx2 promoting infiltration of macrophages into the calcified lesion to form osteoclast-like cells—suggesting that the development of vascular calcification is coupled with the formation of osteoclast-like cells, paralleling the bone remodeling process.<sup>16</sup> The receptor activator of the nuclear factor- $\kappa$ B ligand/osteoprotegerin system controls proper osteoclastogenesis, and acts as a biomarker for CAD.<sup>68,69</sup> Five miRNAs are linked to osteoclastogenesis as well as to cardiovascular disorders. (1) The receptor activator of the nuclear factor- $\kappa$ B ligand is a proposed target of miR-126,<sup>70</sup> which is decreased in the plasma of CAD<sup>19</sup> and T2D<sup>71</sup> patients. (2) miR-155, which is decreased in plasma of CKD<sup>72</sup> and CAD<sup>19</sup> patients, was shown to inhibit osteoclast function in Dicer-deficient osteoclasts.<sup>73</sup> (3) miR-146a, highly expressed in atherosclerotic arteries,<sup>64</sup> inhibits osteoclastogenesis by inhibition of the number of tartrate-resistant acid phosphatase-positive multinucleated cells.<sup>74</sup> (4) miR-223, a key factor in osteoclastogenesis,<sup>75</sup> was found to be increased by Pi treatment of human SMC and in the calcified aorta of *ApoE*-deficient mice.<sup>32</sup> Overexpression of miR-223 enhanced SMC migration, decreased actin cytoskeleton and modulated target genes, like Mef-2 and RhoB. (5) Wang et al demonstrated an association of miR-133a levels in circulating monocytes—osteoclast precursors—with postmenopausal osteoporosis.<sup>76</sup> Women with low bone mineral density showed higher circulating miR-133a levels,<sup>76</sup> but the number of patients per group was small (n=10). Circulating miR-133a levels were also higher in patients with CAD.<sup>19</sup> However, direct links between miR-133a and/or miR-223 and vascular calcification processes have not been reported.

More careful research needs to be conducted to establish direct links between miRNAs and known signaling pathways associated with osteogenic differentiation in the context of cardiovascular calcification. For example, despite the links from different studies noted above, the direct Pi-miR-143/145-KLF4 axis in vascular calcification has not been examined. Additionally, future studies may also lead to a better understanding of the role of miRNA networks in controlling cellular differentiation and ultimate tissue level changes. For instance, though miR-204 is a known inhibitor of osteoblastogenesis, introduction of a mimic agomiR-204 does not alter bone formation in a mouse model of vitamin D3-induced vascular calcification.<sup>28</sup> The observation that miRNAs function in clusters to control cellular and tissue homeostasis may help explain some of the current inconsistencies observed between normal bone formation and vascular calcification (eg, the correlation between osteoporosis and calcification—the calcification paradox). Future miRNA studies may also better connect known signaling pathways associated with osteogenesis to the ultimate pathological outcomes, thereby leading to a deeper understanding of the cellular processes that lead to calcification.

### Circulating miRNAs in Diseases Associated With Vascular Calcification – A Potential miRNA Signature

Our detailed investigation using currently published literature revealed common circulating miRNAs in diseases associated with vascular calcification. We compared miRNA signatures identified in 10 CAD, 4 T2D, and 1 CKD studies (Table 3). From this analysis, 7 miRNAs (miR-21, miR-27, miR-34a, miR-126, miR-146a, miR-155, and miR210) were found to be useful biomarkers shared between at least 2 of the compared diseases, but only miR-21 was common among all three diseases<sup>19,71,72</sup> (Figure 2). miR-21 relates to key processes in the progression of atherosclerosis,<sup>77-79</sup> and predicted targets of miR-21 include BMPR2, which has been linked to atherosclerotic calcification.<sup>80</sup> Atherosclerotic arteries<sup>64</sup> and sclerotic



**Figure 2. Common circulating miRNAs in diseases associated with vascular calcification.** Venn diagram shows overlapping miRNAs identified in at least 2 of the 3 cardiovascular diseases (CRD, chronic renal disease; T2D, type 2 diabetes mellitus; CAD, coronary artery disease). \*Also found in arteriosclerosis obliterans.

intima from lower-extremity vessels<sup>63</sup> expressed higher miR-21 levels than did healthy vessels, whereas circulating levels of miR-21 in atherosclerosis (serum), T2D (plasma), or CKD (plasma) were reduced.<sup>19,71,72</sup> The reason for this opposing observation is not fully understood and requires further investigation. A recent report showed that miRNAs increased in atherosclerotic abdominal aortic aneurysm tissue, whereas reduced levels were found in the circulation.<sup>81</sup> miRNAs packaged inside exosomes or apoptotic bodies may be specifically taken up by diseased tissue, which decreases circulating miRNAs.<sup>82,83</sup>

Of note within the miRNAs shared between 2 of the diseases, miR-146a is an inflammation-related miRNA, implicated in atherosclerosis and osteoclastogenesis.<sup>74</sup> Although circulating miR-146a obtained from peripheral blood mononuclear cells is increased in CAD patients,<sup>84</sup> T2D studies showed controversial results; miR-146a serum levels were increased,<sup>85</sup> and levels in monocytes were decreased.<sup>86</sup> In addition, miR-146a was more highly expressed in atherosclerotic arteries in an animal model<sup>64</sup> and is associated with CKD in vivo.<sup>87</sup> Additionally, miR-155, another inflammation-associated miRNA, was decreased in serum of CAD<sup>19</sup> and plasma of CKD patients.<sup>72</sup> Deficiency of miR155 enhanced atherosclerotic plaque development and decreased plaque stability,<sup>88</sup> suggesting that it acts as an anti-inflammatory and atheroprotective miRNA. miR-155 is also highly expressed in endothelial cells and SMCs, where it targets angiotensin-II receptor.<sup>89</sup> The renin-angiotensin system participates in vascular calcification,<sup>90</sup> and angiotensin-receptor blockade can inhibit arterial calcification by disrupting vascular osteogenesis in vivo.<sup>91</sup> Furthermore, miR-155 repressed osteoblastogenesis by targeting Smad proteins.<sup>46</sup> Thus, high expression of miR-155 may prevent vascular calcification by inhibiting the BMP signaling pathway or the renin-angiotensin system. Comparison of circulating miRNAs in published studies is challenging, mainly because of the different sources of circulating miRNAs, which include serum, whole blood, peripheral blood mononuclear cells, endothelial progenitor cells, and platelets (Table 3) and use different protocols. The miRNA profiles obtained from the different studies, therefore, are often not the same. Future studies need to take a standardized approach to identify circulating miRNAs. In this context, a recent report

suggested the necessity of careful selection for reference miRNAs by showing that hemolysis may significantly affect the levels of plasma miRNAs previously used as endogenous controls.<sup>92</sup> Therefore, hemolysis should be determined, to avoid the phenomenon based on red blood cells.<sup>93</sup> Alternatively, the determination of miRNAs known to be enriched in red blood cells, like miR-451 and miR-16 could be performed.<sup>92</sup> A novel Locked Nucleic Acids-based qPCR method can identify samples affected by sources of preanalytical variation such as cellular contamination.<sup>93</sup>

Allowing for these limitations, a set of circulating miRNAs (consisting of miR-21, miR-27, miR-34a, miR-126, miR-146a, miR-155, and miR-210) is dysregulated in various proinflammatory diseases and may represent a miRNA signature for vascular calcification. Of note, systemic and local inflammation paradoxically affects cardiovascular calcification and bone loss, which supports the concept of inflammation-dependent cardiovascular calcification previously proposed by our group and others.<sup>9,54,94-96</sup> Given the observation that miRNAs often function in clusters and networks,<sup>71</sup> the subset of circulating miRNAs identified in our analysis may turn out to be a portion of a larger network that regulates cardiovascular calcification, wherein the up- or downregulation of a single miRNA is less important than the function of the network as a whole. Using a network analysis, key miRNA clusters may then be identified as the core regulators of the calcification process. Future studies may be able to use this subset as a starting point when trying to compile the larger networks for calcification.


### Extracellular Vesicles in miRNA Transport and Calcification

miRNAs are present in blood (plasma, platelets, erythrocytes, nucleated blood cells) with high stability that is conferred by encapsulation in extracellular vesicles,<sup>97,98</sup> association with a protein complex with the RNA-binding protein Argonaute (Ago) 2,<sup>124</sup> or in lipoprotein complexes (high-density lipoprotein).<sup>99</sup> These associations prevent the degradation of the miRNAs while in the circulation. However, the mechanism by which the majority of miRNAs are transported extracellularly remains controversial. Exported miRNAs are found both within and outside of 16 500 and 120 000g centrifugation pellets, which contains most of the cell-derived vesicles.<sup>97</sup> Other studies showed that the majority of miRNAs are independent of vesicles and copurify with the Ago2 complex, which is known as a key intracellular effector protein of miRNA-mediated RNA silencing.<sup>100,101</sup> Arroyo et al quantified 88 plasma miRNAs (isolated by 120 000g centrifugation, 70 minutes) from healthy donors and found that 90% of them are present in a nonmembrane-bound form.<sup>100</sup> Another study compared microparticles isolated from a 16 000g (90 minutes) centrifugation of plasma from patients with stable CAD and patients with acute coronary syndrome as a control. In CAD patients, most plasma miRNAs associate with extracellular vesicles, and only a small amount are found in extracellular vesicle-free plasma.<sup>102</sup> However, the number of cases is very small (n=5 per group) and a healthy control group is missing. To determine whether the differing patterns of vesicle-associated miRNAs may be used to characterize different diseases, larger study collectives with standardized protocols are needed.

The miRNA pattern found within released vesicles is different from that associated with Ago2 complexes,<sup>100</sup> implicating a cell type-specific miRNA release using different export systems. Depending on the size and type, extracellular vesicles are broadly classified as ectosomes (also called shedding microvesicles), exosomes, matrix vesicles, and apoptotic bodies. Ectosomes are large extracellular vesicles 50 to 100 nm in diameter. Exosomes are small membranous vesicles of endocytic origin with diameter of 40 to 100 nm. Matrix vesicles, which have been shown to calcify, are 30 to 300 nm in diameter and produced by blebbing of the plasma membrane. Apoptotic bodies, 500 to 1000 nm in diameter, are released from fragmented apoptotic cells. Cells may select miRNA and pre-miRNA for cellular release as cargo within these vesicles in a context-dependent manner.<sup>103,104</sup> miRNA profiles of extracellular vesicles are different from their maternal cell profiles, indicating an active mechanism of selective miRNA packing from cells into vesicles,<sup>102</sup> whereas Ago2-miRNA complexes

may be passively produced by dead cells, released by live cells, or actively transported through cell membrane-associated channels or receptors.<sup>105</sup> Additionally, blockade of sphingomyelinase inhibits exosome generation, miRNA secretion, and subsequent intercellular miRNA transfer, implicating a ceramide-dependent mechanism in miRNA packaging and release within extracellular vesicles.<sup>106,107</sup>

Cells use extracellular vesicles to transport miRNA and mediate intercellular communication over long distances or on a local tissue level.<sup>98</sup> Endothelial apoptotic bodies can convey miR-126 to atherosclerotic lesions, demonstrating unique paracrine-signaling function for miRNA during atherosclerosis.<sup>71,83</sup> A recent report provided evidence that miRNA-containing vesicles regulate intercellular communication between endothelial cells and SMCs by selective packaging of the previously discussed regulators of SMC phenotype, miR-143/145, in endothelial cell-derived vesicles that are then transported to SMCs in the vessel wall.<sup>107</sup>



**Figure 3. Alteration of matrix vesicle transport of circulating miRNAs in cardiovascular calcification.**

In physiological conditions (A) or during bone calcification (osteogenesis; B), extracellular vesicles bind to the membrane proteins of the surface of target cells through receptor-ligand interaction, causing signaling processes. They can also fuse with cell-target membrane or bind to surface receptors on target cells with endocytotic internalization by recipient cell, leading to a release of their content into the cytosol of target cells. C, Mechanisms associated with extracellular vesicle-miRNA-mediated pathological calcification. Potential mechanisms associated with extracellular vesicle-miRNA-mediated pathological calcification include the following: (1) a different miRNA packaging into vesicles attributable to the osteogenic environment; (2) increased degradation attributable to increased enzymatic activity within the vesicle; (3) blocked vesicle uptake into the target cell; and (4) uptake in nontarget cells attributable to mineral nucleation on the outer membrane.

**Table 3. Circulating miRNA in Diseases Associated With Vascular Calcification**

miRNA	Disease	Source	Finding	Reference Number
miR-17, -21, -20a, -22a, -27a, -92a, -126, -145, -155, -221, -130a, -208b, let-7d	CAD	Serum	Decreased	19
miR-133a, -208a			Increased	
miR-146a/b	CAD	PBMC	Increased	84
miR-34a	CAD	EPC	Increased	119
miR-221, -222	CAD	EPC	Increased	120
miR-135a, -147	CAD	PBMC	Decreased	22
miR-140, -182	CAD	Whole blood	Decreased	121
miR-122, -370	CAD	Plasma	Increased	122
miR-181a	CAD	Monocytes	Decreased	123
Let-7i	CAD	Monocytes	Decreased	124
miR-340, -624	CAD	Platelets	Increased	125
miR-20b, -21, -24, -29b, -15a, -126, -150, -191, -197, -223, -320, -486	T2D	Plasma	Decreased	71
miR-28-3p			Increased	
miR-146a	T2D	PBMC	Decreased	86
miR-21, -27a, b, -126, -130a	T2D	EPC	Decreased	126
miR-9, -29a, -30d, -34a, -124a, -146a, -375	T2D	Serum	Increased	85
miR-16, -21, -155, -210, -638	CKD	Plasma	Decreased	72
miR-188-5p, -135*, -323-3p, -509-3p, -520-3p, -572, -573, 629*, -632	HC	HDL	Decreased	99
miR-24, -106a, -191, -218, -222, -223, -342-3p, -412, let-7p			Increased	
miR-21, -27b, -130a, -210	AO	Serum	Increased	63

Bold indicates found in >1 study; and italic, found also in tissue (Table 2).

AO indicates arteriosclerosis obliterans; AS, aortic stenosis; CAD, coronary artery disease; CKD, chronic kidney disease; EPC, endothelial progenitor cell; HC, familial hypercholesterolemia; HDL, high-density lipoprotein; PBMC, peripheral blood mononuclear cell; and T2D, type 2 diabetes mellitus.

The mechanism by which miRNAs are received by target cells in a biologically active state is still unknown. In physiological conditions, extracellular vesicles may bind to the membrane proteins of the surface of target cells through receptor–ligand interaction, resulting in intracellular stimulation of genetic pathways. They can also fuse with cell–target membranes and release genetic content in a nonselective manner. Furthermore, vesicles can bind to surface receptors on target cells with endocytotic internalization by recipient cells, followed by fusion with the membranes, leading to a release of their content into the cytosol of target cells and allowing the vesicle contents to directly associate with intracellular components<sup>108</sup> (Figure 3A and 3B).

In addition to their known role as regulators of intercellular communication, extracellular vesicles have also been observed to participate in matrix mineralization. In nonpathological biomineralization in cartilage and bone, chondrocytes and osteoblasts release extracellular vesicles, which serve as nucleation site for hydroxyapatite and initiate mineralization.<sup>109</sup> These structures are also observed in ectopic calcification. The release of vesicles from SMCs is an established key event in the initiation and promotion of SMC calcification.<sup>110</sup> Treatment of SMCs with elevated calcium levels promotes the production of calcifying matrix vesicles, and the loss of fetuin-A, an inhibitor of mineral nucleation.<sup>111</sup> These vesicles act as early nucleation sites for calcification. The phosphatidylserine-membrane complex from SMC-derived and macrophage-derived matrix vesicles redistributes and nucleates hydroxyapatite.<sup>112–114</sup> In addition, hydroxyapatite nanocrystals shed from vesicles may further promote mineralization via

direct effects on the SMC phenotype.<sup>115</sup> Using a proteomic approach it was also shown that calcified extracellular vesicles derived from SMC contain a specific protein profile compared with noncalcifying vesicles,<sup>110</sup> which might be caused by a specific packaging mechanism.

In a pro-osteogenic environment, the specific, physiological vesicle-mediated transport of miRNA in the vasculature may be disturbed through differential miRNA packaging into the vesicles, decreased miRNA stability by increased enzymatic activity (methyl transferase, 3′-5′ exonuclease) within the vesicles, increased matrix vesicle degradation, or blocked or nonspecific uptake of vesicle into the target cell due to mineral nucleation on the outer membrane (Figure 3C). In fact, SMC-derived matrix vesicles have been observed to calcify in a cell-independent manner when exposed to mineralizing conditions on a collagen I substrate.<sup>112</sup> These results may explain the observations of an increased number of matrix vesicles<sup>116</sup> and numerous microcalcifications throughout the collagen I-rich fibrous caps of atherosclerotic plaques.<sup>117</sup> These microcalcifications have been hypothesized to contribute directly to plaque rupture that leads to thrombosis.<sup>118</sup> Given these observations, miRNAs packed in extracellular vesicles may contribute to vascular calcification in two ways. First, vesicles packaged with miRNA for paracrine signaling within the plaque may become entrapped and form microcalcifications. Second, in turn, this may prevent the miRNAs within the vesicles from reaching the intended target cell, leading to phenotypic changes that promote further calcification. Therefore, insight into the underlying mechanism of selective packing of miRNAs into extracellular vesicles and selective uptake into the target



cell will help increase understanding of the role of miRNA-containing vesicles in physiological intercellular communication as well as unintended disruption of this communication, which may prevent calcification in the vascular system.

### Conclusion and Emerging Concepts

In this review, we have discussed an emerging role of miRNAs in cardiovascular calcification, and we have also analyzed the literature of diseases that are known to correlate with calcification in an attempt to establish a potential signature for cardiovascular calcification that should be investigated further. In vitro and in vivo studies have established miRNAs as biomarkers, thereby providing circulating miRNA signatures for different diseases. But these circulating miRNAs may not have biological functions while circulating. Instead, they may act as intercellular communicators, and this communication might be disturbed in calcification disorders, where calcifying matrix vesicles fail to properly deliver miRNAs to the target cell. Studies to fully exploit this potential novel mechanism of cardiovascular calcification are needed.

Moreover, miRNA biology is very complex. Multiple miRNAs can target the same gene (eg, Runx2–miRNA cluster), and one miRNA might have several targets. Only a small amount of these fine-tuned targets may alter biological responses and phenotypes. Understanding the role of miRNA in vascular calcification may be helpful in considering the paradoxical clinical observations of the concurrence of cardiovascular calcification and osteoporosis. Despite its global clinical burden, no medical therapies are available to treat cardiovascular calcification. Targeting of miRNA represents a novel therapeutic opportunity for treating cardiovascular calcification. As cardiovascular calcification and bone remodeling share common mechanisms, we need an in-depth understanding of miRNA function and their association with the molecular pathogenesis of osteoporosis and vascular calcification. This knowledge will be critical for the development of a more specific therapy for cardiovascular calcification that does not adversely affect physiological bone homeostasis.

### Acknowledgments

We thank Sara Karwacki for her editorial assistance.

### Sources of Funding

This work was supported by an American Heart Association (AHA) Scientist Development grant (0835460 N) and by a grant from the National Institutes of Health (NIH; R01HL114805-01), both to Dr Elena Aikawa.

### Disclosures

None.

### References

- Ambros V. The functions of animal microRNAs. *Nature*. 2004;431:350–355.
- Rodriguez A, Griffiths-Jones S, Ashurst JL, Bradley A. Identification of mammalian microRNA host genes and transcription units. *Genome Res*. 2004;14:1902–1910.
- Liang Y, Ridzon D, Wong L, Chen C. Characterization of microRNA expression profiles in normal human tissues. *BMC Genomics*. 2007;8:166.
- Ebert MS, Sharp PA. Emerging roles for natural microRNA sponges. *Curr Biol*. 2010;20:R858–R861.
- Bartel DP. MicroRNAs: target recognition and regulatory functions. *Cell*. 2009;136:215–233.
- Small EM, Olson EN. Pervasive roles of microRNAs in cardiovascular biology. *Nature*. 2011;469:336–342.
- Hjortnaes J, Bouten CV, Van Herwerden LA, Gründeman PF, Kluin J. Translating autologous heart valve tissue engineering from bench to bed. *Tissue Eng Part B Rev*. 2009;15:307–317.
- Sage AP, Tintut Y, Demer LL. Regulatory mechanisms in vascular calcification. *Nat Rev Cardiol*. 2010;7:528–536.
- Aikawa E, Nahrendorf M, Figueiredo JL, Swirski FK, Shtatland T, Kohler RH, Jaffer FA, Aikawa M, Weissleder R. Osteogenesis associates with inflammation in early-stage atherosclerosis evaluated by molecular imaging in vivo. *Circulation*. 2007;116:2841–2850.
- Johnson RC, Leopold JA, Loscalzo J. Vascular calcification: pathobiological mechanisms and clinical implications. *Circ Res*. 2006;99:1044–1059.
- Naik V, Leaf EM, Hu JH, Yang HY, Nguyen NB, Giachelli CM, Speer MY. Sources of cells that contribute to atherosclerotic intimal calcification: an in vivo genetic fate mapping study. *Cardiovasc Res*. 2012;94:545–554.
- Fadini GP, Rattazzi M, Matsumoto T, Asahara T, Khosla S. Emerging role of circulating calcifying cells in the bone-vascular axis. *Circulation*. 2012;125:2772–2781.
- Doehring LC, Heeger C, Aherrahrou Z, Kaczmarek PM, Erdmann J, Schunkert H, Ehlers EM. Myeloid CD34+CD13+ precursor cells transdifferentiate into chondrocyte-like cells in atherosclerotic intimal calcification. *Am J Pathol*. 2010;177:473–480.
- Komori T. Regulation of bone development and extracellular matrix protein genes by RUNX2. *Cell Tissue Res*. 2010;339:189–195.
- Byon CH, Javed A, Dai Q, Kappes JC, Clemens TL, Darley-Usmar VM, McDonald JM, Chen Y. Oxidative stress induces vascular calcification through modulation of the osteogenic transcription factor Runx2 by AKT signaling. *J Biol Chem*. 2008;283:15319–15327.
- Sun Y, Byon C, Yuan K, Chen J, Mao X, Heath JM, Javed A, Zhang K, Anderson PG, Chen Y. Smooth muscle cell-specific runx2 deficiency inhibits vascular calcification. *Circ Res*. 2012.
- Speer MY, Li X, Hiremath PG, Giachelli CM. Runx2/Cbfa1, but not loss of myocardin, is required for smooth muscle cell lineage reprogramming toward osteochondrogenesis. *J Cell Biochem*. 2010;110:935–947.
- Zhang Y, Xie RL, Croce CM, Stein JL, Lian JB, van Wijnen AJ, Stein GS. A program of microRNAs controls osteogenic lineage progression by targeting transcription factor Runx2. *Proc Natl Acad Sci USA*. 2011;108:9863–9868.
- Fichtlscherer S, De Rosa S, Fox H, Schwietz T, Fischer A, Liebetrau C, Weber M, Hamm CW, Röxe T, Müller-Ardogan M, Bonauer A, Zeiher AM, Dimmeler S. Circulating microRNAs in patients with coronary artery disease. *Circ Res*. 2010;107:677–684.
- Bidzhekov K, Gan L, Denecke B, Rostalsky A, Hristov M, Koepfel TA, Zerneck A, Weber C. microRNA expression signatures and parallels between monocyte subsets and atherosclerotic plaque in humans. *Thromb Haemost*. 2012;107:619–625.
- Cipollone F, Felicioni L, Sarzani R, Ucchino S, Spigonardo F, Mandolini C, Malatesta S, Bucci M, Mammarella C, Santovito D, de Lutiis F, Marchetti A, Mezzetti A, Buttitta F. A unique microRNA signature associated with plaque instability in humans. *Stroke*. 2011;42:2556–2563.
- Hoekstra M, van der Lans CA, Halvorsen B, Gullestad L, Kuiper J, Aukrust P, van Berkel TJ, Biessen EA. The peripheral blood mononuclear cell microRNA signature of coronary artery disease. *Biochem Biophys Res Commun*. 2010;394:792–797.
- Goettsch C, Rauner M, Pacyna N, Hempel U, Bornstein SR, Hofbauer LC. miR-125b regulates calcification of vascular smooth muscle cells. *Am J Pathol*. 2011;179:1594–1600.
- Albinsson S, Suarez Y, Skoura A, Offermanns S, Miano JM, Sessa WC. MicroRNAs are necessary for vascular smooth muscle growth, differentiation, and function. *Arterioscler Thromb Vasc Biol*. 2010;30:1118–1126.
- Gui T, Zhou G, Sun Y, Shimokado A, Itoh S, Oikawa K, Muragaki Y. MicroRNAs that target Ca(2+) transporters are involved in vascular smooth muscle cell calcification. *Lab Invest*. 2012;92:1250–1259.
- Lim K, Lu TS, Molostvov G, Lee C, Lam FT, Zehnder D, Hsiao LL. Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23. *Circulation*. 2012;125:2243–2255.
- Huang J, Zhao L, Xing L, Chen D. MicroRNA-204 regulates Runx2 protein expression and mesenchymal progenitor cell differentiation. *Stem Cells*. 2010;28:357–364.

28. Cui RR, Li SJ, Liu LJ, Yi L, Liang QH, Zhu X, Liu GY, Liu Y, Wu SS, Liao XB, Yuan LQ, Mao DA, Liao EY. MicroRNA-204 regulates vascular smooth muscle cell calcification in vitro and in vivo. *Cardiovasc Res*. 2012;96:320–329.
29. Elia L, Quintavalle M, Zhang J, Contu R, Cossu L, Latronico MV, Peterson KL, Indolfi C, Catalucci D, Chen J, Courtneidge SA, Condorelli G. The knockout of miR-143 and -145 alters smooth muscle cell maintenance and vascular homeostasis in mice: correlates with human disease. *Cell Death Differ*. 2009;16:1590–1598.
30. Cordes KR, Sheehy NT, White MP, Berry EC, Morton SU, Muth AN, Lee TH, Miano JM, Ivey KN, Srivastava D. miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. *Nature*. 2009;460:705–710.
31. Boettger T, Beetz N, Kostin S, Schneider J, Krüger M, Hein L, Braun T. Acquisition of the contractile phenotype by murine arterial smooth muscle cells depends on the Mir143/145 gene cluster. *J Clin Invest*. 2009;119:2634–2647.
32. Rangrez AY, M'Baya-Moutoula E, Metzinger-Le Meuth V, Hénaut L, Djelout MS, Benchitrit J, Massy ZA, Metzinger L. Inorganic phosphate accelerates the migration of vascular smooth muscle cells: evidence for the involvement of miR-223. *PLoS ONE*. 2012;7:e47807.
33. Yoshida T, Yamashita M, Hayashi M. Kruppel-like factor 4 contributes to high phosphate-induced phenotypic switching of vascular smooth muscle cells into osteogenic cells. *J Biol Chem*. 2012
34. Cheng Y, Liu X, Yang J, Lin Y, Xu DZ, Lu Q, Deitch EA, Huo Y, Delphin ES, Zhang C. MicroRNA-145, a novel smooth muscle cell phenotypic marker and modulator, controls vascular neointimal lesion formation. *Circ Res*. 2009;105:158–166.
35. Steitz SA, Speer MY, Curinga G, Yang HY, Haynes P, Aebbersold R, Schinke T, Karsenty G, Giachelli CM. Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. *Circ Res*. 2001;89:1147–1154.
36. Santovito D, Mezzetti A, Cipollone F. MicroRNAs and atherosclerosis: new actors for an old movie. *Nutr Metab Cardiovasc Dis*. 2012;22:937–943.
37. Vengrenyuk Y, Carlier S, Xanthos S, Cardoso L, Ganatos P, Virmani R, Einaev S, Gilchrist L, Weinbaum S. A hypothesis for vulnerable plaque rupture due to stress-induced debonding around cellular microcalcifications in thin fibrous caps. *Proc Natl Acad Sci USA*. 2006;103:14678–14683.
38. Hoshino T, Chow LA, Hsu JJ, Perlowski AA, Abedin M, Tobis J, Tintut Y, Mal AK, Klug WS, Demer LL. Mechanical stress analysis of a rigid inclusion in distensible material: a model of atherosclerotic calcification and plaque vulnerability. *Am J Physiol Heart Circ Physiol*. 2009;297:H802–H810.
39. Boström KI, Rajamannan NM, Towler DA. The regulation of valvular and vascular sclerosis by osteogenic morphogens. *Circ Res*. 2011;109:564–577.
40. Boström K, Watson KE, Horn S, Wortham C, Herman IM, Demer LL. Bone morphogenetic protein expression in human atherosclerotic lesions. *J Clin Invest*. 1993;91:1800–1809.
41. Dhore CR, Cleutjens JP, Lutgens E, Cleutjens KB, Geusens PP, Kitslaar PJ, Tordoir JH, Spronk HM, Vermeer C, Daemen MJ. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. *Arterioscler Thromb Vasc Biol*. 2001;21:1998–2003.
42. Balderman JAF, Lee HY, Mahoney CE, Handy DE, White K, Annis S, Lebeche D, Hajjar RJ, Loscalzo J, Leopold JA. Bone morphogenetic protein-2 decreases microRNA-30b and microRNA-30c to promote vascular smooth muscle cell calcification. *J Am Heart Assoc*. 2012;1
43. Nigam V, Sievers HH, Jensen BC, Sier HA, Simpson PC, Srivastava D, Mohamed SA. Altered microRNAs in bicuspid aortic valve: a comparison between stenotic and insufficient valves. *J Heart Valve Dis*. 2010;19:459–465.
44. Yanagawa B, Lovren F, Pan Y, Garg V, Quan A, Tang G, Singh KK, Shukla PC, Kalra NP, Peterson MD, Verma S. miRNA-141 is a novel regulator of BMP-2-mediated calcification in aortic stenosis. *J Thorac Cardiovasc Surg*. 2012;144:256–262.
45. Itoh T, Nozawa Y, Akao Y. MicroRNA-141 and -200a are involved in bone morphogenetic protein-2-induced mouse pre-osteoblast differentiation by targeting distal-less homeobox 5. *J Biol Chem*. 2009;284:19272–19279.
46. Taipaleenmäki H, Bjerre Hokland L, Chen L, Kauppinen S, Kassem M. Mechanisms in endocrinology: micro-RNAs: targets for enhancing osteoblast differentiation and bone formation. *Eur J Endocrinol*. 2012;166:359–371.
47. Monroe DG, McGee-Lawrence ME, Oursler MJ, Westendorf JJ. Update on Wnt signaling in bone cell biology and bone disease. *Gene*. 2012;492:1–18.
48. Miller JD, Chu Y, Brooks RM, Richenbacher WE, Peña-Silva R, Heistad DD. Dysregulation of antioxidant mechanisms contributes to increased oxidative stress in calcific aortic valvular stenosis in humans. *J Am Coll Cardiol*. 2008;52:843–850.
49. Al-Aly Z, Shao JS, Lai CF, Huang E, Cai J, Behrmann A, Cheng SL, Towler DA. Aortic Msx2-Wnt calcification cascade is regulated by TNF-alpha-dependent signals in diabetic Ldlr-/- mice. *Arterioscler Thromb Vasc Biol*. 2007;27:2589–2596.
50. Cheng SL, Shao JS, Halstead LR, Distelhorst K, Sierra O, Towler DA. Activation of vascular smooth muscle parathyroid hormone receptor inhibits Wnt/beta-catenin signaling and aortic fibrosis in diabetic arteriosclerosis. *Circ Res*. 2010;107:271–282.
51. Faverman L, Mikhaylova L, Malmquist J, Nurminskaya M. Extracellular transglutaminase 2 activates beta-catenin signaling in calcifying vascular smooth muscle cells. *FEBS Lett*. 2008;582:1552–1557.
52. Du Y, Gao C, Liu Z, Wang L, Liu B, He F, Zhang T, Wang Y, Wang X, Xu M, Luo GZ, Zhu Y, Xu Q, Wang X, Kong W. Upregulation of a disintegrin and metalloproteinase with thrombospondin motifs-7 by miR-29 repression mediates vascular smooth muscle calcification. *Arterioscler Thromb Vasc Biol*. 2012;32:2580–2588.
53. Boon RA, Seeger T, Heydt S, Fischer A, Hergenreider E, Horrevoets AJ, Vinciguerra M, Rosenthal N, Sciacca S, Pilato M, van Heijningen P, Essers J, Brandes RP, Zeiher AM, Dimmeler S. MicroRNA-29 in aortic dilation: implications for aneurysm formation. *Circ Res*. 2011;109:1115–1119.
54. Aikawa E, Aikawa M, Libby P, Figueiredo JL, Rusanescu G, Iwamoto Y, Fukuda D, Kohler RH, Shi GP, Jaffer FA, Weissleder R. Arterial and aortic valve calcification abolished by elastolytic cathepsin S deficiency in chronic renal disease. *Circulation*. 2009;119:1785–1794.
55. Kapinas K, Kessler C, Ricks T, Gronowicz G, Delany AM. miR-29 modulates Wnt signaling in human osteoblasts through a positive feedback loop. *J Biol Chem*. 2010;285:25221–25231.
56. Kapinas K, Kessler CB, Delany AM. miR-29 suppression of osteonectin in osteoblasts: regulation during differentiation and by canonical Wnt signaling. *J Cell Biochem*. 2009;108:216–224.
57. Glinka A, Wu W, Delius H, Monaghan AP, Blumenstock C, Niehrs C. Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction. *Nature*. 1998;391:357–362.
58. Mukhopadhyay M, Shtrom S, Rodriguez-Esteban C, Chen L, Tsukui T, Gomer L, Dorward DW, Glinka A, Grinberg A, Huang SP, Niehrs C, Izpisua Belmonte JC, Westphal H. Dickkopf1 is required for embryonic head induction and limb morphogenesis in the mouse. *Dev Cell*. 2001;1:423–434.
59. Beazley KE, Deasey S, Lima F, Nurminskaya MV. Transglutaminase 2-mediated activation of beta-catenin signaling has a critical role in warfarin-induced vascular calcification. *Arterioscler Thromb Vasc Biol*. 2012;32:123–130.
60. Thambiah S, Roplekar R, Manghat P, Fogelman I, Fraser WD, Goldsmith D, Hampson G. Circulating sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness. *Calcif Tissue Int*. 2012;90:473–480.
61. Jones JA, Stroud RE, O'Quinn EC, Black LE, Barth JL, Eleftheriades JA, Bavaria JE, Gorman JH III, Gorman RC, Spinale FG, Ikonomidis JS. Selective microRNA suppression in human thoracic aneurysms: relationship of miR-29a to aortic size and proteolytic induction. *Circ Cardiovasc Genet*. 2011;4:605–613.
62. Chen NX, O'Neill KD, Chen X, Kiattisuthorn K, Gattone VH, Moe SM. Activation of arterial matrix metalloproteinases leads to vascular calcification in chronic kidney disease. *Am J Nephrol*. 2011;34:211–219.
63. Li T, Cao H, Zhuang J, Wan J, Guan M, Yu B, Li X, Zhang W. Identification of miR-130a, miR-27b and miR-210 as serum biomarkers for atherosclerosis obliterans. *Clin Chim Acta*. 2011;412:66–70.
64. Raitoharju E, Lyytikäinen LP, Levula M, Oksala N, Mennander A, Tarkka M, Klopp N, Illig T, Kähönen M, Karhunen PJ, Laaksonen R, Lehtimäki T. miR-21, miR-210, miR-34a, and miR-146a/b are up-regulated in human atherosclerotic plaques in the Tampere Vascular Study. *Atherosclerosis*. 2011;219:211–217.
65. Shin V, Zebboudj AF, Boström K. Endothelial cells modulate osteogenesis in calcifying vascular cells. *J Vasc Res*. 2004;41:193–201.
66. Itoh S, Itoh F, Goumans MJ, Ten Dijke P. Signaling of transforming growth factor-beta family members through Smad proteins. *Eur J Biochem*. 2000;267:6954–6967.

67. Eijken M, Swagemakers S, Koedam M, Steenbergen C, Derckx P, Uitterlinden AG, van der Spek PJ, Visser JA, de Jong FH, Pols HA, van Leeuwen JP. The activin A-follistatin system: potent regulator of human extracellular matrix mineralization. *FASEB J*. 2007;21:2949–2960.
68. Mohammadjpour AH, Shamsara J, Nazemi S, Ghadirzadeh S, Shahsavand S, Ramezani M. Evaluation of RANKL/OPG Serum Concentration Ratio as a New Biomarker for Coronary Artery Calcification: A Pilot Study. *Thrombosis*. 2012;2012:306263.
69. Kiechl S, Schett G, Schwaiger J, Seppi K, Eder P, Egger G, Santer P, Mayr A, Xu Q, Willeit J. Soluble receptor activator of nuclear factor-kappa B ligand and risk for cardiovascular disease. *Circulation*. 2007;116:385–391.
70. Dombkowski AA, Sultana Z, Craig DB, Jamil H. In silico analysis of combinatorial microRNA activity reveals target genes and pathways associated with breast cancer metastasis. *Cancer Inform*. 2011;10:13–29.
71. Zampetaki A, Kiechl S, Drozdov I, Willeit P, Mayr U, Prokopi M, Mayr A, Weger S, Oberhollenzer F, Bonora E, Shah A, Willeit J, Mayr M. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. *Circ Res*. 2010;107:810–817.
72. Neal CS, Michael MZ, Pimlott LK, Yong TY, Li JY, Gleadle JM. Circulating microRNA expression is reduced in chronic kidney disease. *Nephrol Dial Transplant*. 2011;26:3794–3802.
73. Mizoguchi F, Izu Y, Hayata T, Hemmi H, Nakashima K, Nakamura T, Kato S, Miyasaka N, Ezura Y, Noda M. Osteoclast-specific Dicer gene deficiency suppresses osteoclastic bone resorption. *J Cell Biochem*. 2010;109:866–875.
74. Nakasa T, Shibuya H, Nagata Y, Niimoto T, Ochi M. The inhibitory effect of microRNA-146a expression on bone destruction in collagen-induced arthritis. *Arthritis Rheum*. 2011;63:1582–1590.
75. Sugatani T, Hruska KA. MicroRNA-223 is a key factor in osteoclast differentiation. *J Cell Biochem*. 2007;101:996–999.
76. Wang Y, Li L, Moore BT, Peng XH, Fang X, Lappe JM, Recker RR, Xiao P. MiR-133a in human circulating monocytes: a potential biomarker associated with postmenopausal osteoporosis. *PLoS ONE*. 2012;7:e34641.
77. Weber M, Baker MB, Moore JP, Searles CD. MiR-21 is induced in endothelial cells by shear stress and modulates apoptosis and eNOS activity. *Biochem Biophys Res Commun*. 2010;393:643–648.
78. Zhou J, Wang KC, Wu W, Subramaniam S, Shyy JY, Chiu JJ, Li JY, Chien S. MicroRNA-21 targets peroxisome proliferators-activated receptor-alpha in an autoregulatory loop to modulate flow-induced endothelial inflammation. *Proc Natl Acad Sci USA*. 2011;108:10355–10360.
79. Fleissner F, Jazbutyte V, Fiedler J, Gupta SK, Yin X, Xu Q, Galuppo P, Kneitz S, Mayr M, Ertl G, Bauersachs J, Thum T. Short communication: asymmetric dimethylarginine impairs angiogenic progenitor cell function in patients with coronary artery disease through a microRNA-21-dependent mechanism. *Circ Res*. 2010;107:138–143.
80. Li X, Yang HY, Giachelli CM. BMP-2 promotes phosphate uptake, phenotypic modulation, and calcification of human vascular smooth muscle cells. *Atherosclerosis*. 2008;199:271–277.
81. Kin K, Miyagawa S, Fukushima S, Shirakawa Y, Torikai K, Shimamura K, Daimon T, Kawahara Y, Kuratani T, Sawa Y. Tissue- and plasma-specific MicroRNA signatures for atherosclerotic abdominal aortic aneurysm. *J Am Heart Assoc*. 2012;1:e000745.
82. Ohyashiki K, Umezaki T, Yoshizawa S, Ito Y, Ohyashiki M, Kawashima H, Tanaka M, Kuroda M, Ohyashiki JH. Clinical impact of down-regulated plasma miR-92a levels in non-Hodgkin's lymphoma. *PLoS ONE*. 2011;6:e16408.
83. Zerneck A, Bidzhekov K, Noels H, Shagdarsuren E, Gan L, Denecke B, Hristov M, Köppel T, Jahantigh MN, Lutgens E, Wang S, Olson EN, Schober A, Weber C. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. *Sci Signal*. 2009;2:ra81.
84. Takahashi Y, Satoh M, Minami Y, Tabuchi T, Itoh T, Nakamura M. Expression of miR-146a/b is associated with the Toll-like receptor 4 signal in coronary artery disease: effect of renin-angiotensin system blockade and statins on miRNA-146a/b and Toll-like receptor 4 levels. *Clin Sci*. 2010;119:395–405.
85. Kong L, Zhu J, Han W, Jiang X, Xu M, Zhao Y, Dong Q, Pang Z, Guan Q, Gao L, Zhao J, Zhao L. Significance of serum microRNAs in pre-diabetes and newly diagnosed type 2 diabetes: a clinical study. *Acta Diabetol*. 2011;48:61–69.
86. Balasubramanyam M, Aravind S, Gokulakrishnan K, Prabu P, Sathishkumar C, Ranjani H, Mohan V. Impaired miR-146a expression links subclinical inflammation and insulin resistance in Type 2 diabetes. *Mol Cell Biochem*. 2011;351:197–205.
87. Ichii O, Otsuka S, Sasaki N, Namiki Y, Hashimoto Y, Kon Y. Altered expression of microRNA miR-146a correlates with the development of chronic renal inflammation. *Kidney Int*. 2012;81:280–292.
88. Donners MM, Wolfs IM, Stöger LJ, van der Vorst EP, Pöttgens CC, Heymans S, Schroen B, Gijbels MJ, de Winther MP. Hematopoietic miR155 deficiency enhances atherosclerosis and decreases plaque stability in hyperlipidemic mice. *PLoS ONE*. 2012;7:e35877.
89. Zhu N, Zhang D, Chen S, Liu X, Lin L, Huang X, Guo Z, Liu J, Wang Y, Yuan W, Qin Y. Endothelial enriched microRNAs regulate angiotensin II-induced endothelial inflammation and migration. *Atherosclerosis*. 2011;215:286–293.
90. Jia G, Stormont RM, Gangahar DM, Agrawal DK. Role of matrix gla protein in angiotensin II-induced exacerbation of vascular stiffness. *Am J Physiol Heart Circ Physiol*. 2012
91. Armstrong ZB, Boughner DR, Drangova M, Rogers KA. Angiotensin II type I receptor blocker inhibits arterial calcification in a pre-clinical model. *Cardiovasc Res*. 2011;90:165–170.
92. Kirschner MB, Kao SC, Edelman JJ, Armstrong NJ, Vallely MP, van Zandwijk N, Reid G. Haemolysis during sample preparation alters microRNA content of plasma. *PLoS ONE*. 2011;6:e24145.
93. Blondal T, Jensby Nielsen S, Baker A, Andreasen D, Mouritzen P, Wrang Teilm T, Dahlsveen IK. Assessing sample and miRNA profile quality in serum and plasma or other biofluids. *Methods*. 2013;59:S1–S6.
94. New SE, Aikawa E. Molecular imaging insights into early inflammatory stages of arterial and aortic valve calcification. *Circ Res*. 2011;108:1381–1391.
95. Hjortnaes J, Butcher J, Figueiredo JL, Riccio M, Kohler RH, Kozloff KM, Weissleder R, Aikawa E. Arterial and aortic valve calcification inversely correlates with osteoporotic bone remodelling: a role for inflammation. *Eur Heart J*. 2010;31:1975–1984.
96. Geng Y, Hsu JJ, Lu J, Ting TC, Miyazaki M, Demer LL, Tintut Y. Role of cellular cholesterol metabolism in vascular cell calcification. *J Biol Chem*. 2011;286:33701–33706.
97. Wang K, Zhang S, Weber J, Baxter D, Galas DJ. Export of microRNAs and microRNA-protective protein by mammalian cells. *Nucleic Acids Res*. 2010;38:7248–7259.
98. Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. *Nat Cell Biol*. 2007;9:654–659.
99. Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. *Nat Cell Biol*. 2011;13:423–433.
100. Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, Mitchell PS, Bennett CF, Pogosova-Agadjanyan EL, Stirewalt DL, Tait JF, Tewari M. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. *Proc Natl Acad Sci USA*. 2011;108:5003–5008.
101. Turchinovich A, Weiz L, Langheinza A, Burwinkel B. Characterization of extracellular circulating microRNA. *Nucleic Acids Res*. 2011;39:7223–7233.
102. Diehl P, Fricke A, Sander L, Stamm J, Bassler N, Htun N, Ziemann M, Helbing T, El-Osta A, Jowett JB, Peter K. Microparticles: major transport vehicles for distinct microRNAs in circulation. *Cardiovasc Res*. 2012;93:633–644.
103. Pigati L, Yaddanapudi SC, Iyengar R, Kim DJ, Hearn SA, Danforth D, Hastings ML, Duelli DM. Selective release of microRNA species from normal and malignant mammary epithelial cells. *PLoS ONE*. 2010;5:e13515.
104. Chen TS, Lai RC, Lee MM, Choo AB, Lee CN, Lim SK. Mesenchymal stem cell secretes microparticles enriched in pre-microRNAs. *Nucleic Acids Res*. 2010;38:215–224.
105. Creemers EE, Tijssen AJ, Pinto YM. Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease? *Circ Res*. 2012;110:483–495.
106. Kosaka N, Iguchi H, Yoshioka Y, Takeshita F, Matsuki Y, Ochiya T. Secretory mechanisms and intercellular transfer of microRNAs in living cells. *J Biol Chem*. 2010;285:17442–17452.
107. Hergenreider E, Heydt S, Tréguer K, Boettger T, Horrevoets AJ, Zeiher AM, Scheffer MP, Frangakis AS, Yin X, Mayr M, Braun T, Urbich C, Boon RA, Dimmeler S. Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAs. *Nat Cell Biol*. 2012;14:249–256.
108. Meckes DG Jr, Raab-Traub N. Microvesicles and viral infection. *J Virol*. 2011;85:12844–12854.
109. Anderson HC. Molecular biology of matrix vesicles. *Clin Orthop Relat Res*. 1995:266–280.



110. Shanahan CM, Crouthamel MH, Kapustin A, Giachelli CM. Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. *Circ Res*. 2011;109:697–711.
111. Reynolds JL, Joannides AJ, Skepper JN, McNair R, Schurgers LJ, Proudfoot D, Jahnke-Dechent W, Weissberg PL, Shanahan CM. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. *J Am Soc Nephrol*. 2004;15:2857–2867.
112. Chen NX, O'Neill KD, Chen X, Moe SM. Annexin-mediated matrix vesicle calcification in vascular smooth muscle cells. *J Bone Miner Res*. 2008;23:1798–1805.
113. Kapustin AN, Davies JD, Reynolds JL, McNair R, Jones GT, Sidibe A, Schurgers LJ, Skepper JN, Proudfoot D, Mayr M, Shanahan CM. Calcium regulates key components of vascular smooth muscle cell-derived matrix vesicles to enhance mineralization. *Circ Res*. 2011;109:e1–12.
114. New SE, Marchini JF, Aikawa M, Shanahan CM, Croce K, Aikawa E. Novel role of macrophage-derived matrix vesicles in arterial microcalcification. *Circulation*. 2011;124:A10866.
115. Sage AP, Lu J, Tintut Y, Demer LL. Hyperphosphatemia-induced nanocrystals upregulate the expression of bone morphogenetic protein-2 and osteopontin genes in mouse smooth muscle cells in vitro. *Kidney Int*. 2011;79:414–422.
116. Bobryshev YV, Killingsworth MC, Lord RS, Grabs AJ. Matrix vesicles in the fibrous cap of atherosclerotic plaque: possible contribution to plaque rupture. *J Cell Mol Med*. 2008;12:2073–2082.
117. Maldonado N, Kelly-Arnold A, Vengrenyuk Y, Laudier D, Fallon JT, Virmani R, Cardoso L, Weinbaum S. A mechanistic analysis of the role of microcalcifications in atherosclerotic plaque stability: potential implications for plaque rupture. *Am J Physiol Heart Circ Physiol*. 2012;303:H619–H628.
118. Maldonado N, Kelly-Arnold A, Cardoso L, Weinbaum S. The explosive growth of small voids in vulnerable cap rupture; cavitation and interfacial debonding. *J Biomech*. 2013;46:396–401.
119. Tabuchi T, Satoh M, Itoh T, Nakamura M. MicroRNA-34a regulates the longevity-associated protein SIRT1 in coronary artery disease: effect of statins on SIRT1 and microRNA-34a expression. *Clin Sci*. 2012;123:161–171.
120. Minami Y, Satoh M, Maesawa C, Takahashi Y, Tabuchi T, Itoh T, Nakamura M. Effect of atorvastatin on microRNA 221 / 222 expression in endothelial progenitor cells obtained from patients with coronary artery disease. *Eur J Clin Invest*. 2009;39:359–367.
121. Taurino C, Miller WH, McBride MW, McClure JD, Khanin R, Moreno MU, Dymott JA, Delles C, Dominiczak AF. Gene expression profiling in whole blood of patients with coronary artery disease. *Clin Sci*. 2010;119:335–343.
122. Gao W, He HW, Wang ZM, Zhao H, Lian XQ, Wang YS, Zhu J, Yan JJ, Zhang DG, Yang ZJ, Wang LS. Plasma levels of lipometabolism-related miR-122 and miR-370 are increased in patients with hyperlipidemia and associated with coronary artery disease. *Lipids Health Dis*. 2012;11:55.
123. Hulsmans M, Sinnaeve P, Van der Schueren B, Mathieu C, Janssens S, Holvoet P. Decreased miR-181a expression in monocytes of obese patients is associated with the occurrence of metabolic syndrome and coronary artery disease. *J Clin Endocrinol Metab*. 2012;97:E1213–E1218.
124. Satoh M, Tabuchi T, Minami Y, Takahashi Y, Itoh T, Nakamura M. Expression of let-7i is associated with Toll-like receptor 4 signal in coronary artery disease: effect of statins on let-7i and Toll-like receptor 4 signal. *Immunobiology*. 2012;217:533–539.
125. Sondermeijer BM, Bakker A, Halliani A, et al. Platelets in patients with premature coronary artery disease exhibit upregulation of miRNA340\* and miRNA624\*. *PLoS ONE*. 2011;6:e25946.
126. Meng S, Cao JT, Zhang B, Zhou Q, Shen CX, Wang CQ. Downregulation of microRNA-126 in endothelial progenitor cells from diabetes patients, impairs their functional properties, via target gene Spred-1. *J Mol Cell Cardiol*. 2012;53:64–72.



# Circulation Research

JOURNAL OF THE AMERICAN HEART ASSOCIATION



## MicroRNA in Cardiovascular Calcification: Focus on Targets and Extracellular Vesicle Delivery Mechanisms

Claudia Goettsch, Joshua D. Hutcheson and Elena Aikawa

*Circ Res.* 2013;112:1073-1084

doi: 10.1161/CIRCRESAHA.113.300937

*Circulation Research* is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231

Copyright © 2013 American Heart Association, Inc. All rights reserved.

Print ISSN: 0009-7330. Online ISSN: 1524-4571

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://circres.ahajournals.org/content/112/7/1073>

An erratum has been published regarding this article. Please see the attached page for:

</content/113/11/e106.full.pdf>

**Permissions:** Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Circulation Research* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the [Permissions and Rights Question and Answer](#) document.

**Reprints:** Information about reprints can be found online at:  
<http://www.lww.com/reprints>

**Subscriptions:** Information about subscribing to *Circulation Research* is online at:  
<http://circres.ahajournals.org/subscriptions/>

# Correction

In the *Circulation Research* article by Goettsch et al (MicroRNA in cardiovascular calcification: focus on targets and extracellular vesicle delivery mechanisms. *Circ Res.* 2013;112:1073–1084. DOI: 10.1161/CIRCRESAHA.113.300937), the authors have found 2 minor errors: In Table 1, miR-30d/e should have been miR-30b/c and on page 1076, miR-30e should have been miR-30c.

The errors have been corrected in the online version of the article, which is available at <http://circres.ahajournals.org/content/112/7/1073.full>.